A Phase IV, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Advagraf (Modified Release Tacrolimus, Once Daily) After Using Prograf (Tacrolimus Twice Daily) in de Novo Liver Transplant Recipients

Trial Profile

A Phase IV, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Advagraf (Modified Release Tacrolimus, Once Daily) After Using Prograf (Tacrolimus Twice Daily) in de Novo Liver Transplant Recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Acronyms Maple
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 08 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 29 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017.
    • 29 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top